Entertainment, Health and Lifestyle

AstraZeneca Cherry-Picked Data, Misrepresented Vaccine’s Efficacy, Independent Medical Board Alleges

An independent panel of medical experts overseeing AstraZeneca’s coronavirus vaccine trial accused the pharmaceutical company of cherry-picking favorable data, The New York Times reported.

The Data and Safety Monitoring Board (DSMB) alleged that AstraZeneca misrepresented the results of its coronavirus vaccine trial when it announced Monday morning that the vaccine had 79% efficacy at preventing symptomatic coronavirus, according to the NYT. The panel wrote a sharply-worded letter to the British pharmaceutical company and U.S. health officials hours after the results were released, triggering the National Institute of Allergy and Infectious Diseases (NIAID) to issue a statement expressing concern.

The DSMB’s letter said AstraZeneca calculated its efficacy rate based on data that was “most favorable for the study as opposed to the most recent and most complete,” the NYT reported.

“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible,” NIAID said in its statement early Tuesday.

AstraZeneca’s coronavirus vaccine, which has been widely administered around the world, may actually have an efficacy rate as low as 69%, DSMB’s letter said, according to the NYT.

“Decisions like this are what erode public trust in the scientific process,” the DSMB wrote in its letter, the NYT reported.

AstraZeneca’s announcement Monday morning highlighted interim results, but didn’t include a complete analysis that was requested by the oversight board, according to the NYT. Members of the board were reportedly taken by surprise by AstraZeneca’s sudden publication of interim results.

But the company said Tuesday that it is planning on releasing full analysis within 48 hours.

“We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis. We are now completing the validation of the statistical analysis,” AstraZeneca said in a statement.

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact licensing@dailycallernewsfoundation.org

Thomas Catenacci

Share
Published by
Thomas Catenacci

Recent Posts

Too Late: WaPo Apologizes For Publishing Hamas Propaganda At Face Value

The Washington Post issued a correction Tuesday, saying it published an article that failed to…

30 minutes ago

Elon Musk Finally Shares His True Feelings About Big, Beautiful Bill

Elon Musk sharply criticized President Donald Trump’s “big, beautiful bill” incorporating vast swathes of his…

41 minutes ago

Trump Says New Iran Deal Will Not Allow Uranium Enrichment, Contradicting Reports

President Donald Trump said Monday night his administration’s new Iran nuclear deal would not include…

42 minutes ago

No, SCOTUS, The Federal Reserve Isn’t An ‘Independent Agency’

The Supreme Court was surely correct in its recent majority decision acknowledging President Trump acted…

54 minutes ago

President Autopen

The Autopen scandal raises many questions: Who was running the country? Are all the pardons…

1 hour ago

Gregg Jarrett Breaks Down Question That Could Determine If Biden Autopen Pardons Are ‘Null And Void’

Fox News legal analyst Gregg Jarrett told “Kudlow” guest host David Asman Monday the answer…

14 hours ago